ETHRIS

Germany
Bayern, Germany, Planegg
+4908989557880 ★

Company profile

ETHRIS company profile

ETHRIS develops mRNA therapeutics with a focus on respiratory diseases and vaccines. ETHRIS possesses an enabling LNP delivery and mRNA modification platform for transcript Therapies. SNIM®RNAis a first-in-class biopharmaceutical which provide a compelling alternative for recombinant protein or gene therapies. SNIM®RNAs encode therapeutic proteins to be produced in the patient‘s body and overcome short duration effects of recombinant proteins. SNIM®RNA Transcript Therapy is a new option for a broad variety of diseases, either acquired or genetically predetermined, lifestyle- or age-related, rare or frequent.

Business identity

Contact email
[email protected]
Phone number
+4908989557880
Operating status
Active
Company type
For Profit
Employee range
00101-00250 employees
Revenue range
$0+
Founded
2009-01-01

Headquarters

Headquarters
Bayern, Germany, Planegg
Postal code
82152
Country code
DE
Continent
Europe

Capital profile

Funding and company signals

Funding rounds
9
Total equity funding
$76.8M
Last funding
Grant / $11.3M / 2025-05-06
Last equity funding
Series Unknown / $5M
Investors
8
Lead investors
4
Founders
2
Articles
42

Founders and investors

Founders

PD Dr. Carsten RudolphProf. Dr. Christian Plank

Lead investors

Bill & Melinda Gates FoundationCiplaEuropean CommissionLaureus Capital

Investors

AstraZenecaBill & Melinda Gates FoundationCiplaEuropean CommissionOrbiMed

People at this company

Preview only. Contact details are available after you sign in.

Log in to view people and contact details at this company

Contact information and company affiliations may no longer be accurate. Verify details before reaching out.

Shipment data

Explore detailed shipment data

Sign in to view shipment history, products, suppliers, and trade lanes for this company.

Log in to view shipment data

Shipment records and coverage can change as the dataset is updated.